Literature DB >> 6659049

Treatment with suramin and 2-substituted 5-nitroimidazoles of chronic murine Trypanosoma brucei infections with central nervous system involvement.

F W Jennings, G M Urquhart, P K Murray, B M Miller.   

Abstract

Mice infected with either of two isolates of Trypanosoma brucei, GVR 23/1 or GVR 35/1, develop a chronic infection in which trypanosomes are localized in the central nervous system. These infected mice were used to evaluate the efficacy of a combination drug treatment comprising suramin and one of three 2-substituted 5-nitroimidazoles. None of the three 5-nitroimidazoles tested alone, cured mice when administered 21 days after infection. However, it was found that T. brucei GVR 23/1 infections could be cured by a single dose of 20 mg/kg suramin followed by a single dose of 80 mg/kg L611,744 [3a,4,5,6,7,8,9,9a-octahydro-3-(1-methyl-5-nitroimidazol-2yl)cycloocta(D) isoxazole]. The single dose of 20 mg/kg suramin had to be followed by four doses of 80 mg/kg L611,744 to cure mice infected with another stabilate, T. brucei GVR 35/1. A single dose of 20 mg/kg suramin followed either by four doses of 250 mg/kg MK 436 [3a,4,5,6,7,7a-hexahydro-3-(1-methyl-5nitro-1H-imidazol-2-yl)-1, 2-benzisoxazole] or four doses of 70 mg/kg of a dihydroxy analogue of MK 436 [cis-3a,4,5,6,7,7a-hexahydro-3-(1-methyl-5-nitro-1H-imidazol-2-yl)-1, 2-benzisoxazole-6,7-diol] also permanently cured all T. brucei GVR 35/1.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6659049     DOI: 10.1016/0035-9203(83)90207-9

Source DB:  PubMed          Journal:  Trans R Soc Trop Med Hyg        ISSN: 0035-9203            Impact factor:   2.184


  7 in total

1.  Characterization of a melamino nitroheterocycle as a potential lead for the treatment of human african trypanosomiasis.

Authors:  Federica Giordani; Annamaria Buschini; Alessandro Baliani; Marcel Kaiser; Reto Brun; Michael P Barrett; Claudia Pellacani; Paola Poli; Ian H Gilbert
Journal:  Antimicrob Agents Chemother       Date:  2014-07-14       Impact factor: 5.191

2.  The use of the 2 substituted 5-nitroimidazole, Fexinidazole (Hoe 239) in the treatment of chronic T. brucei infections in mice.

Authors:  F W Jennings; G M Urquhart
Journal:  Z Parasitenkd       Date:  1983

3.  The use of 2-substituted 5-nitroimidazoles in the treatment of chronic murine Trypanosoma brucei infections with central nervous system involvement.

Authors:  F W Jennings; G M Urquhart; P K Murray; B M Miller
Journal:  Z Parasitenkd       Date:  1984

Review 4.  Anti-trypanosomatid drug discovery: an ongoing challenge and a continuing need.

Authors:  Mark C Field; David Horn; Alan H Fairlamb; Michael A J Ferguson; David W Gray; Kevin D Read; Manu De Rycker; Leah S Torrie; Paul G Wyatt; Susan Wyllie; Ian H Gilbert
Journal:  Nat Rev Microbiol       Date:  2017-02-27       Impact factor: 60.633

5.  The main lytic factor of Trypanosoma brucei brucei in normal human serum is not high density lipoprotein.

Authors:  J Raper; V Nussenzweig; S Tomlinson
Journal:  J Exp Med       Date:  1996-03-01       Impact factor: 14.307

6.  Characterization of a novel trans-sialidase of Trypanosoma brucei procyclic trypomastigotes and identification of procyclin as the main sialic acid acceptor.

Authors:  L C Pontes de Carvalho; S Tomlinson; F Vandekerckhove; E J Bienen; A B Clarkson; M S Jiang; G W Hart; V Nussenzweig
Journal:  J Exp Med       Date:  1993-02-01       Impact factor: 14.307

7.  Discovery of Indoline-2-carboxamide Derivatives as a New Class of Brain-Penetrant Inhibitors of Trypanosoma brucei.

Authors:  Laura A T Cleghorn; Sébastien Albrecht; Laste Stojanovski; Frederick R J Simeons; Suzanne Norval; Robert Kime; Iain T Collie; Manu De Rycker; Lorna Campbell; Irene Hallyburton; Julie A Frearson; Paul G Wyatt; Kevin D Read; Ian H Gilbert
Journal:  J Med Chem       Date:  2015-09-29       Impact factor: 7.446

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.